Click to view each person's full biography.
Chairman of the Board / Member of the Nomination & Compensation Committee / Member of the Audit Committee
Director / Chairman of the Board and Member of the Nomination & Compensation and Audit Committees
Marvyn Robar joined the MedMira Board of Directors in 2014. Mr. Robar, the Company’s first independent director to serve as Chairman, brings extensive experience to the Board with over 35 years in both the private and public sectors. Prior to his retirement from the Government of Nova Scotia in 2013, Mr. Robar served as the Vice President, Investment, Department of Economic and Rural Development and Tourism, in charge of the $700 million economic development fund and as President of the Nova Scotia Strategic Opportunities Fund Inc., a $250 million investment fund. In this role, Mr. Robar had the opportunity to work with many of Nova Scotia’s largest companies as well as a range of small and medium sized enterprises. He routinely provided advice and recommendations to the Executive Council of the Province of Nova Scotia, ministers, and deputy ministers across a broad range of departments on files and portfolios. Mr. Robar earned a BSc in chemistry/math and an MBA from Dalhousie University and holds a chartered accountancy designation.
Director / CEO & Co-Founder
Hermes Chan, CEO & Co-Founder
Hermes Chan, our Chief Executive Officer and Co-Founder, leads our passionate and committed team in driving the strategic direction and growth of MedMira. Mr. Chan, who was named BioScience Innovator of the Year by The Economist in 2007, is the inventor of our patented Rapid Vertical Flow Technology™ platform. Since the company's inception in 1994 Mr. Chan has held progressively senior management roles including Research Scientist, General Manager, Senior Vice President, and Chief Operating Officer. Prior to creating MedMira, he worked with another Canadian biotechnology company in the diagnostics research sector.
Shou-Ching Tang, MD, PhD, FACP, FRCPC
Dr. Shou-Ching Tang, MD, PhD, FACP, FRCPC, is a Professor and Leader of the Breast Cancer Multidisciplinary Program at the Augusta University Cancer Center. He earned his medical degree with honors from West China University of Medical Sciences and a PhD in molecular biology from the University of Alberta in Edmonton, Alberta, Canada. Dr. Tang has held a number of faculty and administrative appointments at medical universities and organizations in Canada and the United States, including The Newfoundland Cancer Treatment Center and Research Foundation, the Atlantic Oncology Group, the University of Minnesota, the Virginia Piper Cancer Institute, Allina Health System, Denver Health Medical Center, University of Colorado, the Mayo College of Medicine, and the University of Miami. He is certified in Internal Medicine and Medical Oncology by both the American Board of Internal Medicine and the Royal College of Physicians and Surgeons of Canada.
Dr. Tang is an experienced researcher whose primary interests include clinical trials in breast and lung cancers and has chaired and participated in many national and international clinical trials. He was the Founding Member of the Breast Cancer International Research Group (BCIRG) and served on its Scientific Advisory Board. Dr. Tang serves as the Associate Editor for the International Journal of Cancer and Clinical Research and an editorial member of the Journal of Cancer Studies and Therapy, the Journal of Modern Oncology and the Chinese Journal of Lung Cancer in addition to publishing extensively in his fields of research. Dr. Tang recently founded the Asia International Breast Cancer Summit (AIBCS) and co-founded the US Chinese Anticancer Association (USCACA). He has held honorary or visiting professorship at academic institutions in Tianjin, Chengdu, Xian, Guangzhou and Shenyang in China and consultant professor in Argentina. Dr. Tang has organized, chaired and spoken at many national and international conferences.
When was MedMira founded?
MedMira was established in 1993.
When did MedMira go public?
MedMira became a publicly traded company in 2000.
Where is MedMira’s stock traded?
MedMira is listed on the TSX Venture Exchange. The exchange symbol is: MIR.
In the USA, the stock can be purchased OTC NASDAQ, the exchange symbol is: MMIRF.
When does MedMira’s fiscal year end?
MedMira’s fiscal year ends July 31.
When does MedMira plan to announce quarterly financial results?
MedMira releases quarterly financial results within 60 days of the quarter ending.
When does MedMira plan to announce annual financial results?
MedMira releases annual financial results within 120 days of the fiscal year ending.
Who can I contact with questions regarding my stock certificates?
For shareholder inquiries regarding stock certificates, change of address, transfer of ownership or other stock account matters, please contact our transfer agent, Computershare Trust Company of Canada at TF. 1 800 564 6253 (in Canada and the United States) or 514 982 7555 (international direct dial) between the hours of 8:30 am and 8:00 pm EST.
Who are MedMira’s independent auditors?
1969 Upper Water Street
Halifax, NS B3J 3R7
T. 1 902 422 8541
Who is MedMira’s transfer agent?
Computershare Trust Company of Canada
1969 Upper Water Street, Suite 2008
Halifax, Nova Scotia B3J 3R7
T. 1 902 420 3557
Where is MedMira’s corporate headquarters?
MedMira’s corporate head office is in Halifax, Nova Scotia, Canada.